[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ECSP088561A - Derivados de pirimidinil-aril-urea que son inhibidores de fgf - Google Patents

Derivados de pirimidinil-aril-urea que son inhibidores de fgf

Info

Publication number
ECSP088561A
ECSP088561A EC2008008561A ECSP088561A ECSP088561A EC SP088561 A ECSP088561 A EC SP088561A EC 2008008561 A EC2008008561 A EC 2008008561A EC SP088561 A ECSP088561 A EC SP088561A EC SP088561 A ECSP088561 A EC SP088561A
Authority
EC
Ecuador
Prior art keywords
pirimidinil
aril
urea derivatives
heteroaryl
fgf inhibitors
Prior art date
Application number
EC2008008561A
Other languages
English (en)
Inventor
Pascal Furet
Guido Bold
Vito Guagnano
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP088561A publication Critical patent/ECSP088561A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La invención se refiere a heteroaril-aril-ureas de la Fórmula (IA), en donde los radicales y símbolos tienen los significados definidos en la presente, al uso de estos compuestos en el tratamiento de enfermedades dependientes de cinasa de proteína; a preparaciones farmacéuticas que comprenden estas heteroaril-aril-ureas; a procesos para la fabricación de estos compuestos novedosos, y a métodos de tratamiento que comprenden el uso de estas heteroaril-aril-ureas.
EC2008008561A 2005-12-21 2008-06-19 Derivados de pirimidinil-aril-urea que son inhibidores de fgf ECSP088561A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US75271105P 2005-12-21 2005-12-21

Publications (1)

Publication Number Publication Date
ECSP088561A true ECSP088561A (es) 2008-07-30

Family

ID=37946774

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008561A ECSP088561A (es) 2005-12-21 2008-06-19 Derivados de pirimidinil-aril-urea que son inhibidores de fgf

Country Status (22)

Country Link
US (2) US8293746B2 (es)
EP (1) EP1976847B1 (es)
JP (1) JP5153645B2 (es)
KR (1) KR101406956B1 (es)
CN (1) CN101336237B (es)
AU (1) AU2006326989B2 (es)
BR (1) BRPI0620408B8 (es)
CA (1) CA2634047C (es)
CR (1) CR10072A (es)
EA (1) EA016438B1 (es)
EC (1) ECSP088561A (es)
GE (1) GEP20105074B (es)
HN (1) HN2008000949A (es)
IL (1) IL192093A0 (es)
MA (1) MA30063B1 (es)
ME (2) MEP3808A (es)
NO (1) NO20083214L (es)
SM (1) SMP200800041B (es)
SV (1) SV2008002967A (es)
TN (1) TNSN08276A1 (es)
WO (1) WO2007071752A2 (es)
ZA (1) ZA200805092B (es)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0512324D0 (en) * 2005-06-16 2005-07-27 Novartis Ag Organic compounds
MEP3808A (xx) * 2005-12-21 2010-02-10 Novartis Ag Derivati pirimidinil aril uree kao fgf inhibitori
CN102666498A (zh) * 2009-08-28 2012-09-12 健泰科生物技术公司 Raf抑制剂化合物及其使用方法
ES2524548T3 (es) * 2009-10-30 2014-12-10 Novartis Ag N-óxido de 3-(2,6-dicloro-3,5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperacin-1-il)-fenilamino]-pirimidin-4-il}-1-metil-urea
AR079257A1 (es) * 2009-12-07 2012-01-04 Novartis Ag Formas cristalinas de 3-(2,6-dicloro-3-5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas
EP2512476A1 (en) * 2009-12-18 2012-10-24 Novartis AG Method for treating haematological cancers
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
EP2821402B1 (en) 2012-02-28 2019-08-21 Astellas Pharma Inc. Nitrogen-containing aromatic heterocyclic compound
GB201204384D0 (en) 2012-03-13 2012-04-25 Univ Dundee Anti-flammatory agents
MX359293B (es) 2012-06-13 2018-09-24 Incyte Holdings Corp Compuestos triciclicos sustituidos como inhibidores del receptor del factor de crecimiento de fibroblastos (fgfr).
US20150203589A1 (en) 2012-07-24 2015-07-23 The Trustees Of Columbia University In The City Of New York Fusion proteins and methods thereof
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
AR094812A1 (es) 2013-02-20 2015-08-26 Eisai R&D Man Co Ltd Derivado de piridina monocíclico como inhibidor del fgfr
AU2014232030B2 (en) * 2013-03-10 2016-05-26 National University Corporation Nagoya University Therapeutic agent for systemic bone disease and use thereof
CA2907243C (en) 2013-03-15 2021-12-28 Celgene Avilomics Research, Inc. Substituted dihydropyrimidopyrimidinone compounds and pharmaceutical compositions thereof use fgfr4 inhibitor
WO2014151734A1 (en) 2013-03-15 2014-09-25 The Trustees Of Columbia University In The City Of New York Fusion proteins and methods thereof
TWI647220B (zh) 2013-03-15 2019-01-11 美商西建卡爾有限責任公司 雜芳基化合物及其用途
SG11201507478VA (en) 2013-03-15 2015-10-29 Celgene Avilomics Res Inc Heteroaryl compounds and uses thereof
EP2789619A1 (en) 2013-04-12 2014-10-15 Kemotech S.r.l. Pharmaceutical compounds wiht angiogenesis inbhibitory activity
SG11201508328PA (en) 2013-04-19 2015-11-27 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
US9783504B2 (en) 2013-07-09 2017-10-10 Dana-Farber Cancer Institute, Inc. Kinase inhibitors for the treatment of disease
WO2015057963A1 (en) 2013-10-18 2015-04-23 Eisai R&D Management Co., Ltd. Fgfr4 inhibitors
EP3060563B1 (en) * 2013-10-25 2018-05-02 Novartis AG Ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors
PT3079667T (pt) 2013-12-13 2019-10-10 Novartis Ag Formas de dosagem farmacêutica
DK3172213T3 (da) 2014-07-21 2021-12-13 Dana Farber Cancer Inst Inc Makrocykliske kinasehæmmere og anvendelser deraf
AU2015292818B2 (en) 2014-07-21 2020-01-16 Dana-Farber Cancer Institute, Inc. Imidazolyl kinase inhibitors and uses thereof
WO2016023014A2 (en) * 2014-08-08 2016-02-11 Dana-Farber Cancer Institute, Inc. Uses of salt-inducible kinase (sik) inhibitors
SG11201700703XA (en) 2014-08-18 2017-03-30 Eisai R&D Man Co Ltd Salt of monocyclic pyridine derivative and crystal thereof
WO2016054483A1 (en) 2014-10-03 2016-04-07 Novartis Ag Use of ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
EP3925979A3 (en) 2014-12-23 2022-03-23 The Trustees of Columbia University in the City of New York Fgfr-tacc fusion proteins and methods thereof
EP3617205B1 (en) 2015-02-20 2021-08-04 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US9802917B2 (en) 2015-03-25 2017-10-31 Novartis Ag Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide
JP6431622B2 (ja) 2015-04-14 2018-11-28 エーザイ・アール・アンド・ディー・マネジメント株式会社 結晶性ｆｇｆｒ４阻害剤化合物およびその使用
CN104803925B (zh) * 2015-04-16 2018-01-12 温州医科大学 一类以fgfr为靶点的2，4，5‑三取代嘧啶类化合物及其制备方法和用途
CA2993022A1 (en) * 2015-07-20 2017-01-26 Taipei Medical University Chlorobenzene substituted azaaryl compounds
CN109071521B (zh) * 2016-01-08 2019-10-25 杭州英创医药科技有限公司 作为fgfr抑制剂的杂环化合物
US11357769B2 (en) 2016-05-10 2022-06-14 Eisai R&D Management Co., Ltd. Drug combinations for reducing cell viability and/or cell proliferation
JP7277357B2 (ja) 2016-07-05 2023-05-18 ザ ブロード インスティテュート，インコーポレーテッド 二環式尿素キナーゼインヒビターおよびそれらの使用
US11241435B2 (en) 2016-09-16 2022-02-08 The General Hospital Corporation Uses of salt-inducible kinase (SIK) inhibitors for treating osteoporosis
MX2019007234A (es) * 2016-12-19 2019-09-06 Epizyme Inc Compuestos heterociclicos sustituidos con amina como inhibidores de ehmt2 y metodos de uso de los mismos.
CA3054809A1 (en) 2017-02-28 2018-09-07 The General Hospital Corporation Uses of pyrimidopyrimidinones as sik inhibitors
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
CA3091153A1 (en) 2018-03-28 2019-10-03 Eisai R&D Management Co., Ltd. Therapeutic agent for hepatocellular carcinoma
BR112020022373A2 (pt) 2018-05-04 2021-02-02 Incyte Corporation sais de um inibidor de fgfr
MX2020011718A (es) 2018-05-04 2021-02-15 Incyte Corp Formas solidas de un inhibidor de receptores del factor de crecimiento de fibroblastos (fgfr) y procesos para prepararlas.
CN109053592B (zh) * 2018-08-07 2020-12-04 温州医科大学 1-(2,5-二甲氧基苯基)-3-(取代嘧啶-4-基)脲类化合物及其制备和应用
CN109053594B (zh) * 2018-08-07 2020-12-18 温州医科大学 1-(3,5-二甲氧基苯基)-3-(取代嘧啶-4-基)脲类化合物及其制备和应用
CN109053593B (zh) * 2018-08-07 2020-12-04 温州医科大学 1-(2,6-氯苯基)-3-(取代嘧啶-4-基)脲类化合物及其制备和应用
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
CN110283130B (zh) * 2019-07-05 2023-12-19 温州医科大学 一种1-(2,5-二甲氧基苯基)-3-取代脲类结肠癌抑制剂及其制备和应用
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US12122767B2 (en) 2019-10-01 2024-10-22 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
JOP20220083A1 (ar) 2019-10-14 2023-01-30 Incyte Corp حلقات غير متجانسة ثنائية الحلقة كمثبطات لـ fgfr
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
CR20220285A (es) 2019-12-04 2022-10-27 Incyte Corp Derivados de un inhibidor de fgfr
US11897891B2 (en) 2019-12-04 2024-02-13 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
JP2024513575A (ja) 2021-04-12 2024-03-26 インサイト・コーポレイション Ｆｇｆｒ阻害剤及びネクチン－４標的化剤を含む併用療法
JP2024522189A (ja) 2021-06-09 2024-06-11 インサイト・コーポレイション Ｆｇｆｒ阻害剤としての三環式ヘテロ環

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3759921A (en) * 1969-10-16 1973-09-18 Lilly Co Eli Method of suppressing immuneresponse with 1 substituted-3-(2 pyrimidyl)ureas
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
ATE396978T1 (de) * 1999-10-07 2008-06-15 Amgen Inc Triazin-kinase-hemmer
ES2282299T3 (es) * 2000-10-20 2007-10-16 EISAI R&D MANAGEMENT CO., LTD. Compuestos aromaticos con anillos de nitrogeno como agentes anticancerigenos.
UA76977C2 (en) 2001-03-02 2006-10-16 Icos Corp Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers
ITMI20010528A1 (it) 2001-03-13 2002-09-13 Istituto Biochimico Pavese Pha Complessi di resveratrolo con fosfolipidi loro preparazione e composizioni farmaceutiche e cosmetiche
US20020156257A1 (en) 2001-03-29 2002-10-24 Chunhua Yan Isolated human Ras-like proteins, nucleic acid molecules encoding these human Ras-like proteins, and uses thereof
GB0201508D0 (en) * 2002-01-23 2002-03-13 Novartis Ag Organic compounds
PE20040522A1 (es) 2002-05-29 2004-09-28 Novartis Ag Derivados de diarilurea dependientes de la cinasa de proteina
US7202244B2 (en) * 2002-05-29 2007-04-10 Millennium Pharmaceuticals, Inc. Chk-1 inhibitors
US20040034038A1 (en) * 2002-08-13 2004-02-19 Goaquan Li Urea kinase inhibitors
AU2003299750A1 (en) 2002-12-20 2004-07-22 Irm Llc Differential tumor cytotoxocity compounds and compositions
US20060004005A1 (en) 2003-09-25 2006-01-05 Sattigeri Viswajanani J Triazines derivatives as cell adhesion inhibitors
PE20051046A1 (es) 2003-11-28 2006-01-11 Novartis Ag Derivados de diaril-urea en el tratamiento de enfermedades dependientes de la quinasa de proteina
BRPI0510032A (pt) 2004-05-20 2007-10-02 Sugen Inc tiofeno heteroaril aminas
UY28931A1 (es) 2004-06-03 2005-12-30 Bayer Pharmaceuticals Corp Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
GB0512324D0 (en) * 2005-06-16 2005-07-27 Novartis Ag Organic compounds
WO2006038112A1 (en) 2004-10-01 2006-04-13 Warner-Lambert Company Llc Use of kinase inhibitors to promote neochondrogenesis
EP1819341A4 (en) 2004-11-10 2011-06-29 Synta Pharmaceuticals Corp IL-12 MODULATORY CONNECTIONS
CA2619366A1 (en) 2005-08-22 2007-03-01 Amgen Inc. Bis-aryl urea compounds for the treatment of protein kinase-mediated diseases
MEP3808A (xx) * 2005-12-21 2010-02-10 Novartis Ag Derivati pirimidinil aril uree kao fgf inhibitori
US20090062320A1 (en) * 2007-08-28 2009-03-05 Vito Guagnano Method of Treating Disorders Mediated by the Fibroblast Growth Factor Receptor

Also Published As

Publication number Publication date
BRPI0620408A2 (pt) 2011-11-08
SV2008002967A (es) 2011-01-24
AU2006326989A1 (en) 2007-06-28
KR101406956B1 (ko) 2014-06-13
GEP20105074B (en) 2010-09-10
NO20083214L (no) 2008-09-01
WO2007071752A3 (en) 2007-11-08
CN101336237A (zh) 2008-12-31
US20130030171A1 (en) 2013-01-31
US20080312248A1 (en) 2008-12-18
CR10072A (es) 2008-08-25
JP2009520768A (ja) 2009-05-28
EP1976847A2 (en) 2008-10-08
MA30063B1 (fr) 2008-12-01
US8759517B2 (en) 2014-06-24
AU2006326989B2 (en) 2011-11-24
MEP3808A (xx) 2010-02-10
ZA200805092B (en) 2009-09-30
CA2634047C (en) 2016-04-12
EA200801565A1 (ru) 2008-12-30
US8293746B2 (en) 2012-10-23
JP5153645B2 (ja) 2013-02-27
BRPI0620408B8 (pt) 2021-05-25
IL192093A0 (en) 2008-12-29
HN2008000949A (es) 2010-11-11
WO2007071752A2 (en) 2007-06-28
CA2634047A1 (en) 2007-06-28
BRPI0620408B1 (pt) 2020-09-15
TNSN08276A1 (en) 2009-10-30
ME00011A (me) 2009-02-10
CN101336237B (zh) 2015-09-30
EA016438B1 (ru) 2012-05-30
SMAP200800041A (it) 2008-07-23
SMP200800041B (it) 2009-07-14
EP1976847B1 (en) 2015-06-17
KR20080090439A (ko) 2008-10-08

Similar Documents

Publication Publication Date Title
ECSP088561A (es) Derivados de pirimidinil-aril-urea que son inhibidores de fgf
CY1120318T1 (el) Υποκατεστημενες βενζυλινδαζολες για χρηση ως αναστολεις κινασης bub1 στη θεραπευτικη αντιμετωπιση υπερπολλαπλασιαστικων ασθενειων
SV2009003299A (es) Derivados de dihidropiridina de utilidad como inhibidores de la proteina quinasa
NO20090628L (no) Pyridizinon derivativater
UY30748A1 (es) Compuesto0s novedosos
EA200801428A1 (ru) Производные пиридиазинона для лечения опухолей
ECSP11011113A (es) Piridiloxi-indoles inhibidores del vegf-r2 y uso de los mismos para el tratamiento de enfermedades
BRPI0510177B8 (pt) composto, composição farmacêutica e uso do mesmo
UY29767A1 (es) Derivados de benzotiazolonas, procesos para su preparación, composiciones farmacéuticas que los contienen y aplicaciones
ECSP077235A (es) Benzamidas sustituidas por trifluoro-metilo como inhibidores de quinasa
UY29803A1 (es) Derivados de adeninas, composiciones farmacéuticas conteniéndolos, procedimientos de preparación y aplicaciones
DK1853602T3 (da) Kemiske forbindelser
DK1853588T3 (da) Kemiske forbindelser
UY32859A (es) Compuestos y composiciones como inhibidores de cinasa de proteina
DOP2006000061A (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
UY29253A1 (es) 3-amino-pirazol(3,4b)piridinas como inhibidores de proteintirosinquinasas, su preparación y uso como medicamento
ECSP088749A (es) Compuestos de tetrahidropiridotienopirimidina y procedimientos de uso de los mismos
CL2008000021A1 (es) Compuestos derivados de 2,4-dianilinopirimidinas, inhibidores de proteinas cinasas; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento o prevencion de enfermedades inflamatorias, diabetes y cancer.
DK2054418T3 (da) Dihydrothieno-pyrimidiner som AKT-proteinkinase-inhibitorer
EA201070424A1 (ru) Хиназолиндионовые производные, их получение и их применения в терапии
EA201201676A1 (ru) Гетероарильные соединения и композиции в качестве ингибиторов протеинкиназы
MA32183B1 (fr) Pyrimidylcyclopentanes hydroxylés utilisés comme inhibiteurs de protéine kinase akt
EA201170344A1 (ru) Азаиндольные ингибиторы iap
DOP2006000024A (es) Tiazolidinonas, su preparación y su uso como medicamento
SE0403086D0 (sv) Compounds